Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

In a new study, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, PAV-617 and PAV-951.

4 Oct 2022

What are the genetic associations of stroke pathogenesis across ancestry groups?

In new research, researchers identified genetic associations of stroke pathogenesis.

4 Oct 2022

Optibrium strengthens global AI drug discovery software operations with three key appointments

Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced three key appointments.

From Optibrium Ltd. 3 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

New algorithm may help predict the risk of Alzheimer's dementia

When people participate in studies of aging, they often want to know what their individual risks of developing dementia from Alzheimer's disease are. Washington University researchers have developed an algorithm that can help provide them with information about what their risks may be.

30 Sep 2022

Changes in temperature may be behind the link between circadian disruption and cancer

Disruptions in circadian rhythm-;the ways that our bodies change in response to the 24-hour light and dark cycle-;have been linked to many different diseases, including cancer.

28 Sep 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

Areas hospitable to Lassa virus spread may extend in the next several decades

In the study, which appeared on September 27 in Nature Communications, scientists analyzed decades of environmental data associated with Lassa virus outbreaks, revealing temperature, rainfall and the presence of pastureland areas as key factors contributing to viral transmission.

27 Sep 2022

Metal compounds could be the solution for drug-resistant fungal infections

University of Queensland researchers say metal compounds could be the answer to the growing problem of drug-resistant fungal infections.

26 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Chemical compounds containing special metals can fight fungal infections

An international collaboration led by researchers from the University of Bern and the University of Queensland in Australia has demonstrated that chemical compounds containing special metals are highly effective in fighting dangerous fungal infections.

23 Sep 2022

Study shows 72% increase in new diagnoses of type 1 diabetes in young COVID-19 patients

Children who were infected with COVID-19 show a substantially higher risk of developing type 1 diabetes (T1D), according to a new study that analyzed electronic health records of more than 1 million patients ages 18 and younger.

23 Sep 2022

Scientists uncover key details of an immune-cell process that underlies excessive inflammation

A team led by Scripps Research scientists has uncovered key details of an immune-cell process that frequently underlies excessive inflammation in the body.

22 Sep 2022

New modeling system identifies potential therapeutics for autosomal recessive polycystic kidney disease

Organoids-;lab grown cells or tissues that resemble organs-;serve as a new tool for disease modeling, but researchers often have difficulty replicating the biophysical conditions in which the organs operate within the body.

22 Sep 2022

SARS-CoV-2 viral infection is associated with an increased risk of Alzheimer’s disease

Older people who were infected with COVID-19 show a substantially higher risk-;as much as 50% to 80% higher than a control group-;of developing Alzheimer's disease within a year, according to a study of more than 6 million patients 65 and older.

14 Sep 2022

The use of AlphaFold2-enabled molecular docking simulations to predict protein-ligand interactions for antibiotic drug discovery

Researchers demonstrated that advances in modeling protein-ligand interactions using machine learning-based approaches are needed to exploit AlphaFold2 for antibiotic discovery better.

9 Sep 2022

New agonistic antibody reduced the amyloid pathology in mice with Alzheimer's disease

A newly developed agonistic antibody reduced the amyloid pathology in mice with Alzheimer's disease, signaling its promise as a potential treatment for the disease, according to a team of researchers at UTHealth Houston.

8 Sep 2022

Study helps reveal the molecular secrets of macular degeneration

Research led by Sanford Burnham Prebys professor Francesca Marassi, Ph.D., is helping to reveal the molecular secrets of macular degeneration, which causes almost 90% of all age-related vision loss.

7 Sep 2022

Creoptix launches new WAVEcontrol software to deliver automated, flexible and intuitive label-free interaction analysis for biologics drug-discovery

Creoptix® (a Malvern Panalytical brand) is announcing the addition of two new wizards to their WAVEcontrol software to simplify and streamline workflows. By combining the high sensitivity, throughput, and no-clog microfluidics of the WAVEsystem, with a faster, more flexible, automated approach to screening and characterization, Creoptix is accelerating biologics drug discovery and diagnostics development.

From Malvern Panalytical 7 Sep 2022

Advances in modeling molecular interactions needed to better harness AlphaFold for drug discovery

Over the past few decades, very few new antibiotics have been developed, largely because current methods for screening potential drugs are prohibitively expensive and time-consuming.

6 Sep 2022